SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Failure, MASH, Obesity, PCOS, and Others | DelveInsight
The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 inhibitors such as YG1699 (Youngene Therapeutics), JP-2266 (Jeil Pharmaceuticals), and others will further propel the SGLT2 inhibitors market. DelveInsight's SGLT2 Inhibitors Market Size, Target Population, Competitive […]